NeuroBo Pharmaceuticals

NeuroBo Pharmaceuticals is a clinical-stage biotechnology company focused on developing innovative therapeutics for unmet medical needs in diabetic neuropathy and Alzheimer's disease. The company's lead candidate, NB-01, is a Phase III-ready drug derived from natural sources that has demonstrated promising efficacy and safety in treating diabetic neuropathic pain, addressing both the symptoms and underlying mechanisms of the condition. Approximately 40 to 50 percent of patients with diabetic peripheral neuropathy experience neuropathic pain, yet existing treatments provide limited relief and have significant adverse effects. NeuroBo is also advancing NB-02, its lead Alzheimer’s drug, which is currently in the IND-enabling stage. This drug has been thoroughly studied in preclinical models, targeting key pathways involved in Alzheimer's disease. With the growing prevalence of these conditions among aging populations, NeuroBo Pharmaceuticals aims to provide effective solutions that not only manage symptoms but also modify the diseases themselves.